Adherium recently received OTC clearance for its Hailie inhaler monitoring platform in the US, and the company says that it has now launched direct-to-consumer sales through a web site. Hailie includes an inhaler sensor and a smartphone app that allows patients to monitor their own inhaler use, and a new web portal will provide health care providers with access to patient group data from Hailie sensors.
The Hailie sensor is approved for use with a number of inhalers, including Symbicort, ProAir HFA, Ventolin HFA, and Flovent HFA. According to the company, it has sold more than 130,000 sensors worldwide.
Adherium CEO Arik Anderson commented, “We’re extremely excited to announce the availability of the full Hailie solution in the US. Individuals and families with asthma and COPD can now access a solution that encompasses the world’s most clinically proven asthma and COPD medication adherence platform, cleverly packaged into the simplest interface. Hailie is the culmination of 15 years of accelerating research and development and is focused on the premise that if we are to turn the corner on treating chronic conditions, we have to make managing them second nature. Today, through advances in technology, the power of real-time feedback, and data science we can cross that last mile in achieving better health – putting medicine to work in the proving ground of everyday life.”
Vitalus Health CEO K. Cody Patel said, “Adherium’s focus on making disease management fit more easily in patients’ lives is a valuable contribution. Adherence technology that fits naturally within a physician’s practice makes care seamless; it fosters a better understanding for patients, meeting a tremendous need.” Adherium announced a collaboration with Vitalus Health, a Texas-based provider of respiratory health services, in May 2018.
Read the Adherium press release.
